Aerie Pharmaceuticals Logo

News & Presentations

UPCOMING EVENTS

CORPORATE PRESENTATIONS

Date Title Documents

Corporate Presentation – April

OIS Dry Eye Innovation Showcase Presentation

Axitinib Implant (AR-14034) Overview

News Releases

Date Title and Summary Additional Formats
Toggle Summary Aerie Pharmaceuticals to Participate in the Bank of America Securities 2021 Healthcare Conference
DURHAM, N.C. --(BUSINESS WIRE)--May 6, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
View HTML
Toggle Summary Aerie Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
First Quarter 2021 Net Revenue Per Bottle of $89 , up 11.3% over Fourth Quarter 2020 First Quarter 2021 Net Revenues of $23.0 Million Increased 12.9% over First Quarter   2020 Significant Progress Made Across the Pipeline Conference Call and Webcast Today, May 5 th , at 5:00 p.m. ET DURHAM, N.C.
View HTML
Toggle Summary Aerie Pharmaceuticals Completes Enrollment of its Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease
Topline results expected in the third quarter of 2021 DURHAM, N.C. --(BUSINESS WIRE)--Apr. 29, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call on Wednesday, May 5, 2021
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 28, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
View HTML
TOP